Other authors have reported that the flavonoid epigallocatechin is able to inhibit tumor cell growth via the PI3K pathway and can be used as a chemotherapeutic [42], a chemopreventive agent [43], or as combinatorial therapy with anti-CTLA4 [44] against CRC. Here, PIK3CD is linked to colorectal carcinoma.